- Home
- ACHL vs DXR Comparison
ACHL vs DXR Comparison
Compare ACHL & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHL
- DXR
- Stock Information
- Founded
- ACHL 2016
- DXR 1970
- Country
- ACHL United Kingdom
- DXR United States
- Employees
- ACHL N/A
- DXR N/A
- Industry
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- DXR Medical/Dental Instruments
- Sector
- ACHL Health Care
- DXR Health Care
- Exchange
- ACHL Nasdaq
- DXR Nasdaq
- Market Cap
- ACHL 46.0M
- DXR 37.6M
- IPO Year
- ACHL 2021
- DXR N/A
- Fundamental
- Price
- ACHL $1.38
- DXR $7.24
- Analyst Decision
- ACHL Buy
- DXR Strong Buy
- Analyst Count
- ACHL 2
- DXR 1
- Target Price
- ACHL $4.00
- DXR $24.75
- AVG Volume (30 Days)
- ACHL 1.9M
- DXR 5.7K
- Earning Date
- ACHL 04-03-2025
- DXR 01-01-0001
- Dividend Yield
- ACHL N/A
- DXR N/A
- EPS Growth
- ACHL N/A
- DXR N/A
- EPS
- ACHL N/A
- DXR 0.35
- Revenue
- ACHL N/A
- DXR $154,205.00
- Revenue This Year
- ACHL N/A
- DXR N/A
- Revenue Next Year
- ACHL N/A
- DXR N/A
- P/E Ratio
- ACHL N/A
- DXR $20.78
- Revenue Growth
- ACHL N/A
- DXR N/A
- 52 Week Low
- ACHL $0.63
- DXR $6.55
- 52 Week High
- ACHL $1.76
- DXR $10.00
- Technical
- Relative Strength Index (RSI)
- ACHL 72.41
- DXR 37.76
- Support Level
- ACHL $1.10
- DXR $7.00
- Resistance Level
- ACHL $1.41
- DXR $7.49
- Average True Range (ATR)
- ACHL 0.02
- DXR 0.33
- MACD
- ACHL 0.00
- DXR -0.01
- Stochastic Oscillator
- ACHL 90.48
- DXR 44.44
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.